Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [517]

Combining immunological and targeted agents in melanoma

Dr Axel Hoos - GlaxoSmithKline, Collegeville, USA

Combining immunological and targeted agents in melanoma ( Dr Axel Hoos - GlaxoSmithKline, Collegeville, USA )

Advances in diagnostic devices in melanoma screening

Dr Alessandro Testori - European Institute of Oncology, Milan, Italy

Advances in diagnostic devices in melanoma screening ( Dr Alessandro Testori - European Institute of Oncology, Milan, Italy )

PD-1 targeting immunotherapy MK-3475 has high, long-lasting activity against...

Dr Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, US

PD-1 targeting immunotherapy MK-3475 has high, long-lasting activity against metastatic melanoma ( Dr Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, US )

Ipilimumab and nivolumab achieves long-term survival in advanced melanoma

Prof Mario Sznol - Yale Cancer Center, New Haven, USA

Ipilimumab and nivolumab achieves long-term survival in advanced melanoma ( Prof Mario Sznol - Yale Cancer Center, New Haven, USA )

Adjuvant ipilimumab improves recurrence-free survival in high-risk stage III...

Prof Alexander M. Eggermont, Erasmus University, Rotterdam, The Netherlands

Adjuvant ipilimumab improves recurrence-free survival in high-risk stage III melanoma ( Prof Alexander M. Eggermont, Erasmus University, Rotterdam, The Netherlands )

Comment: Adjuvant ipilimumab in high-risk melanoma

Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA

Comment: Adjuvant ipilimumab in high-risk melanoma ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )

Comment: PD-1 targeting MK-3475 gives long-term responses in melanoma

Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA

Comment: PD-1 targeting MK-3475 gives long-term responses in melanoma ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )

Comment: Immunotherapy combo increases median survival in advanced melanoma

Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA

Comment: Immunotherapy combo increases median survival in advanced melanoma ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )

Success for ipilimumab and nivolumab combo in advanced melanoma

Prof Mario Sznol - Yale Cancer Center, New Haven, USA

Success for ipilimumab and nivolumab combo in advanced melanoma ( Prof Mario Sznol - Yale Cancer Center, New Haven, USA )

ASCO 2014 roundup

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

ASCO 2014 roundup ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

T-VEC injections into melanoma lesions show significant response rate

Prof Kevin Harrington - Institute of Cancer Research, London, UK

T-VEC injections into melanoma lesions show significant response rate ( Prof Kevin Harrington - Institute of Cancer Research, London, UK )

Cancer evasion of the immune system: the fundamentals

Prof Pedro Romero - Ludwig Institute for Cancer Research, Lausanne, Switzerland

Cancer evasion of the immune system: the fundamentals ( Prof Pedro Romero - Ludwig Institute for Cancer Research, Lausanne, Switzerland )

More from ecancer